RTTNews | Nov 25, 2020 07:48AM EST

07:48 Wednesday, November 25, 2020 (RTTNews.com) - Kantaro Biosciences, a joint venture between the Mount Sinai Health System and RenalytixAI (RNLX), has received Emergency Use Authorization from the FDA for COVID-SeroKlir, its semi-quantitative SARS-CoV-2 IgG antibody test kit. COVID-SeroKlir has showed 98.8% sensitivity and 99.6% specificity for detecting SARS-CoV-2 specific IgG antibodies against two virus antigens. Kantaro noted that, unlike other antibody tests, COVID-SeroKlir determines the presence and precise level of IgG antibodies.

Through a commercial partnership with Bio-Techne Corp. (TECH), the test kits are being manufactured at scale with a capacity of up to 10 million tests per month.

Read the original article on RTTNews ( https://www.rttnews.com/3148661/kantaro-receives-emergency-use-authorization-for-covid-seroklir-igg-antibody-test-kit.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2020 RTTNews.com All Rights Reserved